Anti-FCRL5 Rabbit Polyclonal Antibody for WB, ELISA - Q96RD9

Core Product Specifications and Parameters

Biological Background: FCRL5 Function and Localization

• FCRL5 (Fc receptor-like protein 5), also designated FcRH5, CD307, or IRTA2, is a type I transmembrane receptor of the immunoglobulin superfamily involved in B-cell regulation.
• It functions as a dual-modality B-cell coreceptor: in the absence of complement receptor 2 (CR2) stimulation, FCRL5 inhibits BCR signaling; however, when co-engaged with CR2, it potentiates calcium flux, illustrating context-dependent positive or negative regulation (PubMed:30107486). Related references: PMID:30107486
• FCRL5 is implicated in B-cell development and differentiation in peripheral lymphoid organs, and its expression pattern correlates with specific B-cell maturation stages.
• It is predominantly expressed in marginal zone B-cells, mature and memory B-cells, and is downregulated in germinal center cells, suggesting a role in B-cell homeostasis and antibody response.
• The protein localizes to the cell membrane via a single-pass transmembrane helix, consistent with its function as a cell-surface receptor.
• Multiple protein isoforms are generated by alternative splicing (isoforms 1, 3, 4, and 5), with isoform 3 predominating in lymphoid tissues such as lymph node, spleen, bone marrow, and small intestine.
• Post-translational modifications include N-linked glycosylation and disulfide bond formation, which are important for structural integrity; the receptor also features immunoglobulin domains and a cytoplasmic immunoreceptor tyrosine-based activation/inhibitory signaling motif.
• FCRL5 is overexpressed in certain B-cell lymphomas and hairy cell leukemia, making it a potential diagnostic marker or therapeutic target; a role in fertilization has also been suggested by sequence similarity.

Experimental Guidance and Technical Tips

• For Western blot detection, use reducing conditions and whole cell lysates from human B-cell lines such as Ramos or Raji. The predicted molecular weight is approximately 106 kDa, but glycosylation may cause slight mobility shifts.
• The immunogen encompasses the N-terminal extracellular region (amino acids 16–190), which spans multiple immunoglobulin-like domains, so the antibody is expected to recognize most natural isoforms.
• In ELISA applications, consider using recombinant FCRL5 extracellular domain as a positive control or standard, and validate coating/blocking conditions with relevant biological fluids (e.g., serum, plasma).
• Since this is a polyclonal antibody, it may cross-react with other FCRL family members or related Fc receptor-like proteins. Appropriate negative controls (e.g., FCRL5 knockout lysate) should be used to confirm specificity.
• Cross-reactivity data beyond human samples has not been provided; for other species, users should perform their own verification.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines the sourcing of IVD raw materials, offering diagnostic manufacturers and researchers a single point of access to validated antibodies, recombinant antigens, and supporting reagents. For FCRL5-targeted assay development—whether for B-cell malignancy diagnostics, immune profiling, or research into autoimmune disease—we can supply optimized detection pairs, bulk ancillary reagents, and expert technical consultation. Count on CamelBio to bridge your rare-target material needs from initial concept to clinical application.